Related Experiment Video
Updated: Apr 4, 2026
08:07
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
3.2K
No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other
Dimiter S Dimitrov1, Shibo Jiang2, Tianlei Ying3
1Protein Interactions Group, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702-12011; dimiter.dimitrov@nih.gov shibojiang@fudan.edu.cn.
Abstract
No abstract available in PubMed .
Related Concept Videos
01:31Hybridoma Technology
18.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.6K
00:42Cross-reactivity
33.9K
Overview
33.9K
01:29Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K